Anti-vegf protein compositions and methods for producing the same
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsShunhai Wang, Ning Li, Hunter Chen, Amardeep Singh Bhupender Bhalla, Shawn Lawrence, Amy Johnson, Meghan Casey, Jamie Mastrogiacomo
Life of this patent
Estimating the term…
Abstract
The present disclosure pertains to compositions comprising anti-VEGF proteins.
Claims30
An oxo-aflibercept composition produced in a cell culture media comprising a chemically defined media (CDM), wherein one or more amino acid residues of aflibercept is oxidized and
- wherein said one or more amino acid residues is histidine and/or tryptophan, and
- wherein said oxo-aflibercept has a glycosylation profile based on molar percentage selected from the group consisting of about 40% to about 50% total fucosylated glycans, about 30% to about 55% total sialylated glycans, about 2% to about 15% mannose-5, and about 60% to about 79% galactosylated glycans.
The oxo-aflibercept composition of claim 7, wherein the N-glycosylation of Asn36 of said oxo-aflibercept at SEQ ID NO. 100 is between 98.3% and 99.4%.
A culture media composition comprising chemically defined media (CDM) and oxo-aflibercept, wherein one or more amino acid residues of aflibercept is oxidized and
- wherein said one or more amino acid residues is histidine and/or tryptophan, and
- wherein said oxo-aflibercept has a glycosylation profile based on molar percentage selected from the group consisting of about 40% to about 50% total fucosylated glycans, about 30% to about 55% total sialylated glycans, about 2% to about 15% mannose-5, and about 60% to about 79% galactosylated glycans
A composition comprising oxo-aflibercept, wherein one or more amino acid residues of aflibercept is oxidized and
- wherein said one or more amino acid residues is histidine and/or tryptophan, and
- wherein said oxo-aflibercept has a glycosylation profile based on molar percentage selected from the group consisting of about 40% to about 52.4% total fucosylated glycans, about 30% to about 59.2% total sialylated glycans, about 5.2% to about 15% mannose-5, and about 60% to about 80.6% galactosylated glycans
Dependencies are inferred from the claim text.